ULTRAPROACTIVE THERAPEUTIC DRUG MONITORING BASED ON POINT-OF-CARE TESTING OF INFLIXIMAB IS NOT SUPERIOR TO REACTIVE DRUG MONITORING IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: 1 YEAR RESULTS OF A PRAGMATIC CLINICAL TRIAL

Peter Bossuyt  1     Sophie Claeys  2     Soetkin D'haens  1     Eveline Hoefkens  1     Beatrijs Strubbe  2     Denis Marichal  2     Lieven Pouillon  1     Harald Peeters  3    
1 Imelda GI Clinical Research Center,Bonheiden,Belgium
2 St-Lucas IBD Clinic,Gent,Belgium
3 St-Lucas IBD Cli

Session
IBD: Drug monitoring

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing